Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc. places on The Globe and Mail’s third-annual Women Lead Here benchmark of executive gender diversity

Retrieved on: 
Friday, March 25, 2022
Therapy, Women LEAD, Leadership, Laboratorio museotecnico Goppion, Globe, Business, Parity, Journalism, Woman, TSX, The Globe and Mail, Intention, Businessperson, Woodbridge, GLOBE, Policy, Female, Annual report, Politics, Nature, GUD, Pharmaceutical industry, Drug, Uniting Medically Supervised Injecting Centre, Knight, Report

MONTREAL, March 25, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (Knight or the Company) is pleased to announce it has been recognized in The Globe and Mails 2022 Report on Business Women Lead Here list.

Key Points: 
  • MONTREAL, March 25, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (Knight or the Company) is pleased to announce it has been recognized in The Globe and Mails 2022 Report on Business Women Lead Here list.
  • This annual editorial benchmark identifies best-in-class executive gender diversity in corporate Canada.
  • We are honored to be recognized by The Globe and Mail as one of Canadas Women Lead Here, said Samira Sakhia, President and Chief Executive Officer of Knight.
  • At Knight, we believe that diversity is the over-arching value that we all need to strive towards.

Notice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference Call

Retrieved on: 
Thursday, March 17, 2022
GUD, Therapy, TSX, Nature, Laboratorio museotecnico Goppion, Annual report, Intention, Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Key Points: 
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries.
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia

Retrieved on: 
Thursday, January 6, 2022
Perampanel, Therapy, Tumor hypoxia, HIV disease progression rates, Patient, Anthracycline, Adult, Eribulin, Intention, Cancer, GUD, Annual report, Breast cancer, TSX, Leiomyosarcoma, Phenotype, Gene, Liposarcoma, Woman, Museo-laboratorio della Civiltà Contadina (Museum-workshop of the Peasant Culture), OS, GLOBE, Halichondrin B, Taxane, Nature, Pharmaceutical industry, Medical imaging, Knight, Uniting Medically Supervised Injecting Centre, Eisai

MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (Knight or the Company) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven (eribulin) injection.

Key Points: 
  • MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (Knight or the Company) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven (eribulin) injection.
  • Halaven (eribulin) injection has shown to significantly improve overall survival in patients with advanced or metastatic breast cancer after anthracycline and taxane treatment.
  • Were pleased to announce the approval of Halaven (eribulin) injection in Colombia as it provides a new treatment option for metastatic breast cancer and liposarcoma, said Samira Sakhia, President & Chief Executive Officer.
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com .

Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia

Retrieved on: 
Tuesday, January 4, 2022
RET, Pembrolizumab, Sorafenib, HIV disease progression rates, Hepatocellular carcinoma, FGF, RCC, GLOBE, KDR, VEGFR1, Nature, Thymic carcinoma, Radiation, Liver cancer, Progression-free survival, Lenvatinib, KIT, Annual report, Everolimus, Therapy, VEGFR3, Thyroid cancer, Adult, Patient, FLT1, GUD, Iodine, Laboratorio museotecnico Goppion, Intention, Cancer, Renal cell carcinoma, VEGF, FLT4, TSX, Pharmaceutical industry, Knight, Uniting Medically Supervised Injecting Centre, Eisai

In addition, Lenvima (lenvatinib) was statistically significantly superior to sorafenib for progression-free survival and objective response rate.

Key Points: 
  • In addition, Lenvima (lenvatinib) was statistically significantly superior to sorafenib for progression-free survival and objective response rate.
  • In 2020, there were approximately 5,3043 new patients with thyroid cancer and 2,2893 new patients with liver cancer in Colombia.
  • Were pleased to announce the approval of Lenvima (lenvatinib) in Colombia as it provides a new treatment option for radioiodine refractory differentiated thyroid cancer and unresectable hepatocellular carcinoma, said Samira Sakhia, President & Chief Executive Officer.
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com .

The 18th edition of NYTFF hits the red carpet with celebrities from Turkey

Retrieved on: 
Tuesday, December 14, 2021
ADA, Red Bridge (border), Uniting Medically Supervised Injecting Centre, Letter, Crime, Border, IRIS, SVA, Love, CHOBANI, EKOS, Lunch, ATS, Multimedia, Final Draft, American Turkish Society, Film, Entertainment, Geranium

The festival, which was enhanced by a hybrid screening model to reach an even broader audience both in person and online, consisted of socially-conscious films from diverse storytellers.

Key Points: 
  • The festival, which was enhanced by a hybrid screening model to reach an even broader audience both in person and online, consisted of socially-conscious films from diverse storytellers.
  • This year's festival theme "Bridges & Borders" was inspired by the urge to bridge the gap between cultures, identities and people in our polarized and divided world.
  • Designer Berkcan Okar of Yer Creative created a design that reflected the theme successfully.
  • Organized by POLTIO, the audience choice award was given to the feature film "Not Knowing" directed by Leyla Yilmaz.